CAJ | 학술논문

口服抗凝药在心脑血管血栓疾病的防治中发挥了重要作用，新型口服抗凝药包括直接凝血酶抑制剂达比加群，Xa因子抑制剂利伐沙班、阿哌沙班、贝曲西班和依杜沙班，无需监测、相互作用少，循证医学试验证实在术后血栓、心房颤动，以及急性冠脉综合征中疗效及安全性好于华发林、依诺肝素等，不良反应小。
구복항응약재심뇌혈관혈전질병적방치중발휘료중요작용，신형구복항응약포괄직접응혈매억제제체비가군，Xa인자억제제리벌사반、아고사반、패곡서반화의두사반，무수감측、상호작용소，순증의학시험증실재술후혈전、심방전동，이급급성관맥종합정중료효급안전성호우화발림、의낙간소등，불량반응소。
Oral anticoagulants play an important role in the prevention and managment of heart and cerebral thrombosis disease. New oral anticoagulants including dabigatran etexilate (direct thrombin inhibitor) and inhibition of factor Xa such as rivaroxaban, apixaban, edoxaban and betrixaban. Monitoring is not necessary and less interaction is found in these new oral anticoagulants. Evidence-based medical tests confirm that new oral anticoagulants are more safety and efficacy and less adverse reactions than warfarin and enoxaparin on postoperative blood clots, atrial fibril ation and acute coronary syndrome.